Heat shock protein-90 (HSP90) is an ATP-dependent molecular chaperone with intrinsic ATPase activity. HSP90 is required for the stability and function of client proteins, many of which are involved in oncogenesis. Thus, identification of HSP90 inhibitors would potentially lead to the discovery of cancer therapeutics. Here, we present a high-throughput screening campaign utilizing two geldanamycin (GM)-labeled probes in a fluorescence polarization (FP) assay. For the primary screen, a previously reported green BODIPY-labeled GM (GM-BODIPY) was used to evaluate a library collection of about 400,000 compounds. From this screen, 3058 compounds showed >30% inhibition. To distinguish true positives from compound interference, a confirmatory screen was deemed necessary. Accordingly, a red-shifted FP binding assay was developed using GM labeled with red BODIPY. This tool enabled reliable identification of promising HSP90α inhibitors.
Get full access to this article
View all access options for this article.
References
1.
WorkmanP, BurrowsF, NeckersL, RosenN. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci, 2007; 1113:202–216.
2.
XiaoL, LuX, RudenDM. Effectiveness of Hsp90 inhibitors as anti-cancer drugs. Mini Rev Med Chem, 2006; 6:1137–1143.
3.
PearlLH, ProdromouC, WorkmanP. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J, 2008; 410:439–453.
4.
KamalA, ThaoL, SensintaffarJ, ZhangL, BoehmMF, FritzLC, BurrowsFJ. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature, 2003; 425:407–410.
5.
WazaM, AdachiH, KatsunoM, MinamiyamaM, TanakaF, SobueG. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG)Ann NY Acad Sci, 2006; 1086:21–34.
6.
SharpS, WorkmanP. Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res, 2006; 95:323–348.
7.
ProdromouC, RoeSM, O'BrienR, LadburyJE, PiperPW, PearlLH. Identification and structural characterization of the ATP/ADP-binding site in the HSP90 molecular chaperone. Cell, 1997; 90:65–75.
8.
HaddenMK, LubbersDJ, BlaggBS. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site. Curr Top Med Chem, 2006; 6:1173–1182.
9.
SchnurRC, CormanML, GallaschumRJ, CooperBA, DeeMF, DottyJL, MuzziML, MoyerJD, DiOrioCI, BarbacciEG, MillerPE, O'BrienAT, MorinMJ, FosterBA, PollackVA, SavageDM, SloanDE, PustilnikLR, MoyerMP. Inhibition of the oncogene product p185erb-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem, 1996; 38:3806–3812.
10.
TianZ-Q, LiuY, ZhangD, WangZ, DongSD, CarrerasCW, ZhouY, RastelliG, SantiDV. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Biorg Med Chem, 2004; 12:5317–5329.
11.
SausvilleEA, TomaszewskiJE, IvyP. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets, 2003; 3:377–383.
12.
RamanathanRK, EgorinMJ, ErlichmanC, RemickSC, RamalingamSS, NaretC, HolleranJL, TenEyckCJ, IvySP, BelaniCP. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol, 2010; 28:1520–1526.
13.
HowesR, BarrilX, DymockBW, GrantK, NorthfieldCJ, RobertsonAG, SurgenorA, WayneJ, WrightL, JamesK, MatthewsT, CheungKM, McDonaldE, WorkmanP, DrysdaleMJ. A fluorescence polarization assay for inhibitors of Hsp90. Anal Biochem, 2006; 350:202–213.
KimJ, FeltsS, LlaugerL, HeH, HuezoH, RosenN, ChiosisG. Development of a fluorescence polarization assay for the molecular chaperone Hsp90. J Biomol Screen, 2004; 9:375–381.
16.
ZhouV, HanS, BrinkerA, KlockH, CaldwellJ, GuXJ. A time-resolved fluorescence resonance energy transfer-based HTS assay and a surface plasmon resonance-based binding assay for heat shock protein 90 inhibitors. Anal Biochem, 2004; 331:349–357.
17.
FangY, PingjunZ, SouthallN, IngleseJ, AustinCP, WeiZ, ReganL. An AlphaScreen™-based high-throughput screen to identify inhibitors of Hsp90-cochaperone interaction. J Biomol Screen, 2009; 14:273–281.
18.
RowlandsMG, NewbattYM, ProdromouC, PearlLH, WorkmanP, AherneW. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem, 2004; 327:176–183.
19.
RowlandsMG, McAndrewC, ProdromouC, PearlL, KalusaA, JonesK, WorkmanP, AherneW. Detection of the ATPase activity of the molecular chaperones Hsp90 and Hsp72 using the Transcreener™ ADP assay kit. J Biomol Screen, 2010; 15:279–286.
20.
AvilaC, KornilayevBA, BlaggBS. Development and optimization of a useful assay for determining Hsp90's inherent ATPase activity. Bioorg Med Chem, 2006; 14:1134–1142.
21.
AvilaC, HaddenM K, MaZ, KornilayevBA, YeQZ, BlaggBS. High-throughput screening for Hsp90 ATPase inhibitors. Bioorg Med Chem Lett, 2006; 16:3005–3008.
VedvikKL, EliasonHC, HoffmanRL, GibsonJR, KupchoKR, SombergRLet al.Overcoming compound interference in fluorescence polarization-based kinase assays using far-red tracers. Assay Drug Dev Technol, 2004; 2:193–203.
24.
BoldyrevIA, ZhaiX, MomsenMM, BrockmanHL, BrownRE, MolotkovskyJG. New BODIPY lipid probes for fluorescence studies of membranes. J Lipid Res, 2007; 48:1518–1532.
25.
Llauger-BufiL, FeltsSJ, HuezoH, RosenN, ChiosisG. Synthesis of novel fluorescent probes for the molecular chaperone Hsp90. Bioorg Med Chem Lett, 2003; 13:3975–3978.
26.
BanksP, HarveyM. Considerations for using fluorescence polarization in the screening of G protein-coupled receptors. J Biomol Screen, 2002; 7:111–117.
27.
QianJ, VoorbachMJ, HuthJR, CoenML, ZhangH, NgSC, ComessKM, PetrosAM, RosenbergSH, WarriorU, BurnsDJ. Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms. Anal Biochem, 2004; 328:131–138.
28.
Corning Life Sciences Catalog. http://catalog2.corning.com/Lifesciences/media/pdf/poster11_16_01_black_10ul_1536%20perfmini_fluorpolar_hts.pdf. 2012 January 28.
29.
ZhangJH, ChungTD, OldenburgKR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen, 1999; 4:67–73.
30.
LiH, MandichakT, SiegfriedB, HofmannG, SchneckJ, VillaJ, ArnoneM, KingAJ, GooljarsinghL, FernandesC, TumminoP, ZhangH, JohansonK, BurtonG, MacarronR. Identification of Hsp90 inhibitors with potentially novel mechanism(s) through the use of two High Throughput Screens. Poster presented at the SBS 12th Annual Conference and Exhibition, Seattle, 2006.
31.
AllenM, ReevesJ, MellorG. High throughput fluorescence polarization: a homogeneous alternative to radioligand binding for cell surface receptors. J Biomol Screen, 2000; 5:63–69.
32.
MoulickK, ClementCC, AguirreJ, KimJ, KangY, FeltsS, ChiosisG. Synthesis of a red-shifted fluorescence polarization probe for Hsp90. Bioorg Med Chem Lett, 2006; 16:4515–4518.
